Statins and other agents for vascular inflammation.

Area of Science:

• Cardiovascular Medicine
• Inflammation Research
• Pharmacology

Background:

• Atherosclerosis and its clinical outcomes are increasingly understood as inflammatory conditions.
• Circulating inflammatory biomarkers, particularly high-sensitivity C-reactive protein, independently predict cardiovascular risk.
• Statins reduce cardiovascular risk and inflammatory markers, but their effects are confounded by cholesterol reduction.

Purpose of the Study:

• To evaluate the hypothesis that targeted anti-inflammatory therapies can improve cardiovascular outcomes.
• To investigate novel anti-inflammatory agents that reduce inflammatory markers without impacting lipids, glucose, or blood pressure.

Main Methods:

• Review of clinical trials investigating statins as anti-inflammatory agents.
• Analysis of ongoing trials for novel anti-inflammatory drugs.
• Examination of inflammatory biomarkers in cardiovascular risk prediction.

Main Results:

• High-sensitivity C-reactive protein is a robust predictor of cardiovascular risk.
• Statin trials provide a basis for testing specific anti-inflammatory agents.
• Novel agents aim to reduce inflammation without altering metabolic parameters.

Conclusions:

• Targeting inflammation is a promising strategy for cardiovascular risk reduction.
• Future trials with specific anti-inflammatory drugs will clarify the role of inflammation in vascular disease.
• Understanding the inflammation-vascular risk relationship is crucial for developing new therapies.